

Express Mail No. EV138528660US

Date of Deposit: November 27, 2002

Attorney Docket No. 15966-577A CIP3 (CURA-77A CIP3)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Shimkets et al.

SERIAL NO.: 09/775,482

EXAMINER: Janet L. Andres

FILING DATE: February 2, 2001

ART UNIT: 1646

FOR: GROWTH FACTOR POLYPEPTIDES AND NUCLEIC ACIDS ENCODING SAME

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

DEC 05 2002

TRANSMITTAL LETTER


TECH CENTER 1600/2900

Transmitted herewith for filing in the above-identified application:

1. Response to Office Action mailed June 28, 2002 (11 pages);
2. Petition for Extension of Time for two months (in duplicate);
3. Check No. 14749 in the amount of \$200.00 to cover extension fee; and
4. Return Postcard.

The Commissioner is hereby authorized to charge payment of any filing fees required in connection with the papers transmitted herewith, or credit any overpayment of same, to Deposit Account No. 50-0311 Reference No. 15966-577A CIP3, (CURA-77A CIP3). A duplicate copy of this transmittal letter is transmitted herewith.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Kristin E. Konzak, Reg. No. 44,848
Attorney/Agent for Applicant
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Date: November 27, 2002


Please address all written correspondence to customer number 30623.



30623

PATENT TRADEMARK OFFICE

Express Mail Label No.: EV138528600US
Deposit Date: November 27, 2002



PATENT APPLICATION
ATTY DOCKET 15966-577A CIP3 (CURA-77A CIP3)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Shimkets *et al.*
SERIAL NUMBER : 09/775,482 EXAMINER : Janet Andres, Ph.D.
FILING DATE : February 2, 2001 ART UNIT : 1646
FOR : Growth Factor Polypeptides and Nucleic Acids Encoding Same

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

DEC 05 2002

TECH CENTER 1600/2300

AMENDMENT AND RESPONSE

This filing is in response to the June 28, 2002 Office Action ("Office Action"). Please enter the following amendments and consider the remarks prior to further prosecution.

AMENDMENTS

In the specification:

Please replace the paragraph on page 128, lines 9-16, with the following:

-- Amino terminal sequence analysis of p35 demonstrated proteolytic cleavage after Arg247 (R247) or Arg249 (R249) residues of SEQ ID NO:2 (FIG. 15). As indicated in Panel A of FIG. 15, two peptides were found, one beginning with GlyArg (*i.e.* GRSYHDR ... (SEQ ID NO:23), shown with the Gly248-Arg249 residues underlined), which corresponds to the p35 polypeptide product resulting from a cleavage after R247 of SEQ ID NO:2, and the second beginning with the third residue, Ser250 (*i.e.* SYHDR ...), of SEQ ID NO:23, which corresponds to the p35 polypeptide product resulting from a cleavage after R249 of SEQ ID NO:2. The ratio of these peptides was found to be SYHDR:GRSYHDR = 4:1. The additional sequencing results in FIG. 15 (Panels B and C) (SEQ ID NOS:24-25, beginning with Gly248, and SEQ ID NOS:26-27, beginning with Arg341) indicate that further processing produces the remaining polypeptides seen with Coomassie blue staining but not with anti-V5 Westerns, namely the 16 kDa and 6 kDa species shown. These are joined together to provide p35. --

Pursuant to 37 C.F.R. 1.121(b), a marked up version of the specification showing the changes made appears as Appendix A of this Amendment.